Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model

American Journal of Pathology

Volumn 181, Issue 2, 2012, Pages 706-718

  Krishna, Smriti M ^a   Seto, Sai Wang ^a   Moxon, Joseph V ^a   Rush, Catherine ^a   Walker, Philip J ^b   Norman, Paul E ^c   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ARCH; APOPTOSIS; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; BLOOD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; IMMUNOCOMPETENT CELL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE; UPREGULATION; VASODILATATION;

ANGIOTENSIN II; ANIMALS; AORTA; AORTA, THORACIC; AORTIC ANEURYSM, ABDOMINAL; APOPTOSIS; AZO COMPOUNDS; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FENOFIBRATE; INFLAMMATION; KIDNEY; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TREATMENT OUTCOME; UP-REGULATION;

EID: 84864148446     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.04.015     Document Type: Article

References (80)

1. Chichester Aneurysm Screening Group Viborg Aneurysm Screening Study; Western Australian Abdominal Aortic Aneurysm Program; Multicentre Aneurysm Screening Study: a comparative study of the prevalence of abdominal aortic aneurysms in the United Kingdom, Denmark, and Australia J Med Screen 8 2001 46 50
2. F.R. Arko, W.A. Lee, B.B. Hill, C. Olcott 4th, R.L. Dalman, E.J. Harris Jr, P. Cipriano, T.J. Fogarty, C.K. Zarins Aneurysm-related death: primary endpoint analysis for comparison of open and endovascular repair J Vasc Surg 36 2002 297 304
3. R.M. Greenhalgh, L.C. Brown, G.P. Kwong, J.T. Powell, S.G. Thompson EVAR trial participants Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial Lancet 364 2004 843 848
4. J.D. Blankensteijn, S.E. de Jong, M. Prinssen, A.C. van der Ham, J. Buth, S.M. van Sterkenburg, H.J. Verhagen, E. Buskens, D.E. Grobbee Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms N Engl J Med 352 2005 2398 2405
5. EVAR trial participants Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial Lancet 365 2005 2187 2192
6. J.S. Lindholt, J. Sorensen, R. Sogaard, E.W. Henneberg Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial Br J Surg 97 2010 826 834
7. J. Golledge, P.E. Norman Current status of medical management for abdominal aortic aneurysm Atherosclerosis 217 2011 57 63
8. United Kingdom Small Aneurysm Trial Participants Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms N Engl J Med 346 2002 1445 1452
9. J. Golledge, F. van Bockxmeer, K. Jamrozik, M. McCann, P.E. Norman Association between serum lipoproteins and abdominal aortic aneurysm Am J Cardiol 105 2010 1480 1484
10. M. Rizzo, P.A. Krayenbühl, V. Pernice, A. Frasheri, G. Battista Rini, K. Berneis LDL size and subclasses in patients with abdominal aortic aneurysm Int J Cardiol 134 2009 406 408
11. A. Wanhainen, D. Bergqvist, K. Boman, T.K. Nilsson, J. Rutegård, M. Björck Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data J Vasc Surg 41 2005 390 396
12. G. Simoni, A. Gianotti, A. Ardia, A. Baiardi, R. Galleano, D. Civalleri Screening study of abdominal aortic aneurysm in a general population: lipid parameters Cardiovasc Surg 4 1996 445 448
13. H.G. Alcorn, S.K. Wolfson Jr, K. Sutton-Tyrrell, L.H. Kuller, D. O'Leary Risk factors for abdominal aortic aneurysms in older adults enrolled in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 16 1996 963 970
14. K. Singh, K.H. Bonaa, B.K. Jacobsen, L. Bjork, S. Solberg Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromso Study Am J Epidemiol 154 2001 236 244
15. A.D. Blann, C. Devine, J. Amiral, C.N. McCollum Soluble adhesion molecules, endothelial markers and atherosclerosis risk factors in abdominal aortic aneurysm: a comparison with claudicants and healthy controls Blood Coagul Fibrinolysis 9 1998 479 484
16. G. Assmann, A.M. Gotto Jr HDL cholesterol and protective factors in atherosclerosis Circulation 109 23 Suppl 1 2004 III8 III14
17. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100
18. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 2004 764 772
19. P. Keul, K. Sattler, B. Levkau HDL and its sphingosine-1-phosphate content in cardioprotection Heart Fail Rev 12 2007 301 306
20. A.C. Mulders, M.C. Hendriks-Balk, M.J. Mathy, M.C. Michel, A.E. Alewijnse, S.L. Peters Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II Arterioscler Thromb Vasc Biol 26 2006 2043 2048
21. J.S. Karliner Sphingosine kinase and sphingosine 1-phosphate in cardioprotection J Cardiovasc Pharmacol 53 2009 189 197
22. Y.C. Levine, G.K. Li, T. Michel Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells Evidence for an AMPK -> Rac1 -> Akt -> endothelial nitric-oxide synthase pathway J Biol Chem 282 2007 20351 20364
23. T. Kimura, H. Tomura, K. Sato, M. Ito, I. Matsuoka, D.S. Im, A. Kuwabara, C. Mogi, H. Itoh, H. Kurose, M. Murakami, F. Okajima Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells J Biol Chem 285 2010 4387 4397
24. T.M. Davis, R. Ting, J.D. Best, M.W. Donoghoe, P.L. Drury, D.R. Sullivan, A.J. Jenkins, R.L. O'Connell, M.J. Whiting, P.P. Glasziou, R.J. Simes, Y.A. Kesäniemi, V.J. Gebski, R.S. Scott, A.C. Keech Fenofibrate Intervention and Event Lowering in Diabetes Study investigators Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
25. V. Ribas, X. Palomer, N. Roglans, N. Rotllan, C. Fievet, A. Tailleux, J. Julve, J.C. Laguna, F. Blanco-Vaca, J.C. Escolà-Gil Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate Biochim Biophys Acta 1737 2005 130 137
26. H. Duez, Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fiévet, S.D. Wright, B. Staels Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice J Biol Chem 277 2002 48051 48057
27. J. Golledge, B. Cullen, C. Moran, C. Rush Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm Cardiovasc Drugs Ther 24 2010 373 378
28. C. Rush, M. Nyara, J.V. Moxon, A. Trollope, B. Cullen, J. Golledge Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm BMC Genomics 10 2009 298
29. J. Golledge, B. Cullen, C. Rush, C.S. Moran, E. Secomb, F. Wood, A. Daugherty, J.H. Campbell, P.E. Norman Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm Atherosclerosis 210 2010 51 56
30. M. Sobczak, J. Dargatz, M. Chrzanowska-Wodnicka Isolation and culture of pulmonary endothelial cells from neonatal mice J Vis Exp 46 2010 2316
31. P. Delerive, J.C. Fruchart, B. Staels Peroxisome proliferator-activated receptors in inflammation control J Endocrinol 169 2001 453 459
32. Y.X. Wang, B. Martin-McNulty, V. da Cunha, J. Vincelette, X. Lu, Q. Feng, M. Halks-Miller, M. Mahmoudi, M. Schroeder, B. Subramanyam, J.L. Tseng, G.D. Deng, S. Schirm, A. Johns, K. Kauser, W.P. Dole, D.R. Light Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis Circulation 111 2005 2219 2226
33. D. Gavrila, W.G. Li, M.L. McCormick, M. Thomas, A. Daugherty, L.A. Cassis, F.J. Miller Jr, L.W. Oberley, K.C. Dellsperger, N.L. Weintraub Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 25 2005 1671 1677
34. B. Martin-McNulty, D.M. Tham, V. da Cunha, J.J. Ho, D.W. Wilson, J.C. Rutledge, G.G. Deng, R. Vergona, M.E. Sullivan, Y.X. Wang 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 23 2003 1627 1632
35. E.F. Steinmetz, C. Buckley, M.L. Shames, T.L. Ennis, S.J. Vanvickle-Chavez, D. Mao, L.A. Goeddel, C.J. Hawkins, R.W. Thompson Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice Ann Surg 241 2005 92 101
36. N. Inoue, M. Muramatsu, D. Jin, S. Takai, T. Hayashi, H. Katayama, Y. Kitaura, H. Tamai, M. Miyazaki Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice Atherosclerosis 204 2009 359 364
37. R.S. Rosenson, D.A. Wolff, A.L. Huskin, I.B. Helenowski, A.W. Rademaker Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome Diabetes Care 30 2007 1945 1951
38. A. Uchida, M.N. Slipchenko, J.X. Cheng, K.K. Buhman Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, alters triglyceride metabolism in enterocytes of mice Biochim Biophys Acta 1811 2011 170 176
39. H. Duez, Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fiévet, S.D. Wright, B. Staels Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice J Biol Chem 277 2002 48051 48057
40. S. Pyne, N.J. Pyne Sphingosine 1-phosphate signalling in mammalian cells Biochem J 349 2000 385 402
41. J.D. Saba, T. Hla Point-counterpoint of sphingosine 1-phosphate metabolism Circ Res 94 2004 724 734
42. K. Watterson, H. Sankala, S. Milstien, S. Spiegel Pleiotropic actions of sphingosine-1-phosphate Prog Lipid Res 42 2003 344 357
43. T.A. Taha, K.M. Argraves, L.M. Obeid Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy Biochim Biophys Acta 1682 2004 48 55
44. B. Zhang, H. Tomura, A. Kuwabara, T. Kimura, S. Miura, K. Noda, F. Okajima, K. Saku Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins Atherosclerosis 178 2005 199 205
45. S. Jiao, T.G. Cole, R.T. Kitchens, B. Pfleger, G. Schonfeld Genetic heterogeneity of plasma lipoproteins in the mouse: control of low density lipoprotein particle sizes by genetic factors J Lipid Res 31 1990 467 477
46. K.A. Dugi, B.L. Vaisman, N. Sakai, C.L. Knapper, S.M. Meyn, H.B. Brewer Jr, S. Santamarina-Fojo Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice J Lipid Res 38 1997 1822 1832
47. H.V. de Silva, J. Más-Oliva, J.M. Taylor, R.W. Mahley Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse J Lipid Res 35 1994 1297 1310
48. A.M. Scanu, C. Edelstein HDL: bridging past and present with a look at the future FASEB J 22 2008 4044 4054
49. C. Christoffersen, H. Obinata, S.B. Kumaraswamy, S. Galvani, J. AhnströM, M. Sevvana, C. Egerer-Sieber, Y.A. Muller, T. Hla, L.B. Nielsen, B. Dahlbäck Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M Proc Natl Acad Sci USA 108 2011 9613 9618
50. J.R. Nofer, M. van der Giet, M. Tölle, I. Wolinska, K. von Wnuck Lipinski, H.A. Baba, U.J. Tietge, A. Gödecke, I. Ishii, B. Kleuser, M. Schäfers, M. Fobker, W. Zidek, G. Assmann, J. Chun, B. Levkau HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 2004 569 581
51. R. Tao, H.E. Hoover, N. Honbo, M. Kalinowski, C.C. Alano, J.S. Karliner, R. Raffai High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate Am J Physiol Heart Circ Physiol 298 2010 H1022 H1028
52. T. Kimura, C. Mogi, H. Tomura, A. Kuwabara, D.S. Im, K. Sato, H. Kurose, M. Murakami, F. Okajima Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells J Immunol 181 2008 7332 7340
53. H.H. Chao, C.H. Chen, J.C. Liu, J.W. Lin, K.L. Wong, T.H. Cheng L-Carnitine attenuates angiotensin II-induced proliferation of cardiac fibroblasts: role of NADPH oxidase inhibition and decreased sphingosine-1- phosphate generation J Nutr Biochem 21 2010 580 588
54. Z. Huang, X. Zhou, A.C. Nicholson, A.M. Gotto Jr, D.P. Hajjar, J. Han Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor Br J Pharmacol 155 2008 596 605
55. H. Murakami, R. Murakami, F. Kambe, X. Cao, R. Takahashi, T. Asai, T. Hirai, Y. Numaguchi, K. Okumura, H. Seo, T. Murohara Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC Biochem Biophys Res Commun 341 2006 973 978
56. A. Tomizawa, Y. Hattori, T. Inoue, S. Hattori, K. Kasai Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation Metabolism 60 2011 513 522
57. A. Tabernero, K. Schoonjans, L. Jesel, I. Carpusca, J. Auwerx, R. Andriantsitohaina Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation BMC Pharmacol 2 2002 10
58. K. Goya, S. Sumitani, X. Xu, T. Kitamura, H. Yamamoto, S. Kurebayashi, H. Saito, H. Kouhara, S. Kasayama, I. Kawase Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells Arterioscler Thromb Vasc Biol 24 2004 658 663
59. K.K. Koh, M.J. Quon, R.S. Rosenson, W.J. Chung, S.H. Han Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates Int J Cardiol 124 2008 149 159
60. P. Balakumar, M.K. Arora, M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol Res 60 2009 170 173
61. J. Kaur, K. Reddy, P. Balakumar The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat Cardiovasc Toxicol 10 2010 227 238
62. R.K. Upmacis, H. Shen, L.E. Benguigui, B.D. Lamon, R.S. Deeb, K.A. Hajjar, D.P. Hajjar Inducible nitric oxide synthase provides protection against injury-induced thrombosis in female mice Am J Physiol Heart Circ Physiol 301 2011 H617 H624
63. G. Pascual, A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, C.K. Glass A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
64. L. Tao, H.R. Liu, E. Gao, Z.P. Teng, B.L. Lopez, T.A. Christopher, X.L. Ma, I. Batinic-Haberle, R.N. Willette, E.H. Ohlstein, T.L. Yue Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia Circulation 108 2003 2805 2811
65. A. Daugherty, M.W. Manning, L.A. Cassis Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice J Clin Invest 105 2000 1605 1612
66. K. Maiellaro, W.R. Taylor The role of the adventitia in vascular inflammation Cardiovasc Res 75 2007 640 648
67. L. Zhao, M.P. Moos, R. Gräbner, F. Pédrono, J. Fan, B. Kaiser, N. John, S. Schmidt, R. Spanbroek, K. Lötzer, L. Huang, J. Cui, D.J. Rader, J.F. Evans, A.J. Habenicht, C.D. Funk The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm Nat Med 10 2004 966 973
68. J.R. Nofer, G. Assmann Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids Trends Cardiovasc Med 15 2005 265 271
69. J. Igarashi, M. Miyoshi, T. Hashimoto, Y. Kubota, H. Kosaka Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins Br J Pharmacol 150 2007 470 479
70. J.E. Hughes, S. Srinivasan, K.R. Lynch, R.L. Proia, P. Ferdek, C.C. Hedrick Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages Circ Res 102 2008 950 958
71. A.M. Whetzel, D.T. Bolick, S. Srinivasan, T.L. Macdonald, M.A. Morris, K. Ley, C.C. Hedrick Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor Circ Res 99 2006 731 739
72. M. Tölle, B. Levkau, P. Keul, V. Brinkmann, G. Giebing, G. Schönfelder, M. Schäfers, K. von Wnuck Lipinski, J. Jankowski, V. Jankowski, J. Chun, W. Zidek, M. Van der Giet Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3 Circ Res 96 2005 913 920
73. M. González-Díez, C. Rodríguez, L. Badimon, J. Martínez-González Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin Thromb Haemost 100 2008 119 126
74. A. López-Candales, D.R. Holmes, S. Liao, M.J. Scott, S.A. Wickline, R.W. Thompson Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms Am J Pathol 150 1997 993 1007
75. V.L. Rowe, S.L. Stevens, T.T. Reddick, M.B. Freeman, R. Donnell, R.C. Carroll, M.H. Goldman Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas J Vasc Surg 31 2000 567 576
76. A. Daugherty, M.W. Manning, L.A. Cassis Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis Br J Pharmacol 134 2001 865 870
77. J. Satta, A. Mennander, Y. Soini Increased medial TUNEL-positive staining associated with apoptotic bodies is linked to smooth muscle cell diminution during evolution of abdominal aortic aneurysms Ann Vasc Surg 16 2002 462 466
78. J.Y. Kong, S.W. Rabkin Reduction of palmitate-induced cardiac apoptosis by fenofibrate Mol Cell Biochem 258 2004 1 13
79. Y. Irukayama-Tomobe, T. Miyauchi, S. Sakai, Y. Kasuya, T. Ogata, M. Takanashi, M. Iemitsu, T. Sudo, K. Goto, I. Yamaguchi Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway Circulation 109 2004 904 910
80. D.S. De Silva, R.M. Wilson, C. Hutchinson, P.C. Ip, A.G. Garcia, S. Lancel, M. Ito, D.R. Pimentel, F. Sam Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms Am J Physiol Heart Circ Physiol 296 2009 H1983 H1993